Genfit is a biopharmaceutical company focused on the discovery and development of therapeutics and diagnostic tools for rare and life-threatening liver diseases. The company's pipeline targets Acute-on-Chronic Liver Failure (ACLF), cholangiocarcinoma, urea cycle disorders, and organic acidemia. Its lead asset, elafibranor, is marketed as Iqirvo for Primary Biliary Cholangitis under a licensing agreement with Ipsen, which also develops the drug for Primary Sclerosing Cholangitis. Genfit holds a diagnostic franchise for Metabolic dysfunction-associated steatohepatitis (MASH) and ammonia monitoring, with the NIS technology commercialized by Labcorp as NASHnext. The company operates through its subsidiary Genfit Corp in the United States and acquired Versantis AG in 2022 to expand its clinical-stage portfolio. Founded in 1999, Genfit maintains R&D sites in France, Switzerland, and the United States.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage genfit.com
Sector Healthcare IR page ir.genfit.com
Tags
liver diseases, primary biliary cholangitis, acute-on-chronic liver failure, cholangiocarcinoma, diagnostics, metabolic dysfunction-associated steatohepatitis, rare diseases, clinical stage, Iqirvo, elafibranor, Genfit Corp, Versantis AG, NASHnext, NIS, GNS561, SRT-015, CLM-022, G1090N, nangibotide, nitazoxanide, VS-01-HAC, EViv, VS-02-HE
Press page —

Metrics

Valuation  
Market cap € 459.948M
Market cap (USD) $ 511.784M
P/E -4.50
PEG —
P/BV -9.48
P/S 7.84
P/OCF -17.53
P/FCF -16.65
Dividend yield —
Turnover / mcap —
Returns  
ROE 381.5%
ROI —
ROIC —
Profit margin -120.9%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 71.115M 70.939M 38.176M 26.566M 85.579M 7.758M 40.961M
Net profit -85.968M 1.507M -28.894M -23.719M 67.259M -101.221M -65.144M
Free cash flow -27.628M 14.57M -55.843M -72.889M 99.378M -97.271M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 7.96 — 3.68 3.49 3.42 — —
Price performance 12m — — 0.05 0.02 — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 11.9M 7.24M 15.9M 32.7M 7.56M 40.3M
↳ YoY growth -39.3% +119.8% +105.6% -76.9% +433.2%
↳ 5y CAGR +27.6%
Borrowings, non-current (EUR) — 169M 47.7M 49.9M 52.2M — —
Cash and deposits (EUR) 277M 171M 259M 136M 77.8M 81.8M 101M
Intangible assets (EUR) — 297,000 174,000 44M 48.8M 48M 4.16M
Net debt (borrowings + leases - cash) (EUR) — -1.56M -211M -86.1M -25.6M — —
Cash flow detail
Operating cash flow (EUR) — -96.4M 99.9M -72.6M -55.4M 15.5M -26.2M
Purchases of property, plant and equipment (EUR) — -900,000 -537,000 -251,000 -414,000 -979,000 -1.39M
Purchases of intangible assets (EUR) — — — 0.00 -2.07M 0.00 -2.03M
Change in receivables (cash effect) (EUR) — 318,000 4.34M -8.57M -17.4M 24M -32.7M
Change in payables (cash effect) (EUR) — -11.4M 55.3M -46.2M -10.4M -15.5M 11.9M
Interest paid (cash effect) (EUR) — -7.76M -2.11M -2.18M -2.2M -2.13M -575,000
Income taxes paid (cash effect) (EUR) — 0.00 0.00 -145,000 -465,000 -74,000 0.00
Share-based compensation (EUR) — 1.24M 470,000 245,000 578,000 610,000 308,000
Operating cash flow before change in receivables (EUR) — -96.7M 95.6M -64.1M -38M -8.42M 6.49M
Free cash flow (OCF - PPE - intangibles) (EUR) — -97.3M 99.4M -72.9M -57.9M 14.6M -29.7M
Income detail
Research and development expense (EUR) — 59.1M 35.2M 35.8M 46.5M 47.2M 103M
↳ 5y CAGR +11.8%
Total comprehensive income (EUR) -65.3M -101M 67.6M -24.8M -27.4M -272,000 -85.9M
Comprehensive income to owners (EUR) — -101M 67.6M -24.8M — — —
Reported Apr 29, 2022 Apr 29, 2022 Apr 29, 2022 Apr 5, 2024 Apr 5, 2024 Apr 29, 2025 Apr 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Genfit S.A. (ticker GNFT), listed in France.

ETFs Holding Genfit S.A.

ETF Weight in ETF Shares Market value As of
AVDE 0.00% 21,455 $ 247.221K Nov 16, 2026
AVSD 0.00% 334 $ 3,848.60 Nov 16, 2026